Traduction de «since 2007 – which include lucentis » (Néerlandais → Français) :

Products launched since 2007 – which include Lucentis, Exforge, Exelon Patch, Exjade, Reclast/Aclasta, Tekturna/Rasilez, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris and Fanapt – now comprise 22% of division sales compared to 18% in the 2009 quarter.
Les produits lancés depuis 2007 – qui comprennent Lucentis, Exforge, Exelon Patch, Exjade, Aclasta/Reclast, Rasilez/Tekturna, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris et Fanapt – représentent actuellement 22% des ventes de la division, contre 18% au trimestre comparable de 2009.

These products launched since 2007 – which include Lucentis, Exforge, Exelon Patch, Exjade, Reclast/Aclasta, Tekturna/Rasilez, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris and Fanapt – contributed substantially to the division’s 7% cc net sales growth in the quarter.
Lancés depuis 2007, ces produits – qui comprennent Lucentis, Exforge, Exelon Patch, Exjade, Aclasta/Reclast, Rasilez/Tekturna, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris et Fanapt – ont contribué substantiellement à la croissance de 7% tcc du chiffre d’affaires net du trimestre.

Products launched since 2007 – which include Lucentis, Exforge, Exelon Patch, Exjade, Reclast/Aclasta, Tekturna/Rasilez, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris and Fanapt – grew by 43% compared to the same period last year.
Les produits lancés depuis 2007 – qui comprennent Lucentis, Exforge, Exelon Patch, Exjade, Aclasta/Reclast, Rasilez/Tekturna, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris et Fanapt – ont progressé de 43% par rapport au trimestre comparable de 2009.

Income from associated companies The decline in income from associated companies in the first half of 2009 resulted mainly from reduced contributions from the Roche stake, which included a negative adjustment of USD 40 million since Roche’s reported 2008 results were lower than anticipated.
Résultat provenant des sociétés associées Le repli du résultat provenant des sociétés associées au premier semestre 2009 est dû essentiellement à une réduction des contributions issues de la participation dans Roche, qui incluaient un ajustement à la baisse d’USD 40 millions des résultats de Roche présentés en 2008, lesquels avaient été inférieurs aux attentes.

Research & Development investments rose at a slower pace than net sales in the quarter, falling 0.4 percentage points to 23.0% of net sales compared to the 2007 period, which included partial impairments of various In-Process R&D assets.
Au quatrième trimestre, les investissements en R&D ont augmenté moins vite que le chiffre d’affaires net en baissant à 23,0% du chiffre d’affaires net, soit de 0,4 point de pourcentage par comparaison avec quatrième trimestre 2007. Celui-ci incluait en effet des pertes de valeur partielles d’actifs R&D acquis.

Other Income & Expenses, net, fell to 2.1% of net sales from 8.0% in the 2007 quarter, which included a Forward restructuring charge of USD 307 million.
Le poste Autres produits et charges, nets, a chuté à 2,1% du chiffre d’affaires net contre 8,0% au quatrième trimestre 2007, qui comprenait des charges de restructuration Forward d’USD 307 millions.

Lucentis (USD 886 million, +122% lc), a biotechnology eye therapy now approved in more than 70 countries, has delivered dynamic growth since its first European launch in early 2007.
Lucentis (USD 886 millions, +122% en m. l.), traitement oculaire biotechnologique disponible dans plus de 70 pays, a connu une croissance vigoureuse depuis son premier lancement en Europe début 2007.

This increase makes it possible to move from the 2007 inspection schedule, which was the weakest ever since the introduction of these arrangements, to a more optimistic one for 2008.
This increase makes it possible to move from the 2007 inspection schedule, which was the weakest ever since the introduction of these arrangements, to a more optimistic one for 2008.

In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.
In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.